Literature DB >> 2217957

Gout and hyperuricemia.

R Roubenoff1.   

Abstract

The prevalence of gout in the United States has been rising steadily for the past two decades. Hyperuricemia is considered a necessary but not sufficient precondition for gout. Known risk factors for gout include male sex, hypertension, renal insufficiency, obesity/weight gain, diuretic use, lead exposure, and family history. The association of gout and hyperuricemia with coronary artery disease is controversial. Current evidence from the Framingham Study suggests that gout is in fact an independent risk factor for CHD. These data suggest that patients with gout should be screened for modifiable risk factors for CHD, and that early intervention in such patients may be worthwhile. Finally, the effect of AHU as risk factor for CHD remains unclear but is probably a weak one.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2217957

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  25 in total

1.  Characteristics of gouty arthritis in the Guatemalan population.

Authors:  C O Garcia; A G Kutzbach; L R Espinoza
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

Review 2.  Diet, alcohol, and gout: how do we advise patients given recent developments?

Authors:  Hyon K Choi
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 3.  Tophaceous gout in the elderly: a clinical case review.

Authors:  Francesco Bolzetta; Nicola Veronese; Enzo Manzato; Giuseppe Sergi
Journal:  Clin Rheumatol       Date:  2012-02-25       Impact factor: 2.980

4.  Gout is on the increase in New Zealand.

Authors:  P Klemp; S A Stansfield; B Castle; M C Robertson
Journal:  Ann Rheum Dis       Date:  1997-01       Impact factor: 19.103

5.  Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.

Authors:  Michael Chen-Xu; Chio Yokose; Sharan K Rai; Michael H Pillinger; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2019-04-15       Impact factor: 10.995

Review 6.  Pathophysiology, clinical presentation and treatment of gout.

Authors:  Gim Gee Teng; Raj Nair; Kenneth G Saag
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort.

Authors:  Hadar Duskin-Bitan; Eytan Cohen; Elad Goldberg; Tzippy Shochat; Amos Levi; Moshe Garty; Ilan Krause
Journal:  Clin Rheumatol       Date:  2014-02-13       Impact factor: 2.980

8.  Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.

Authors:  Reza Khosravan; Brian Grabowski; Jing-Tao Wu; Nancy Joseph-Ridge; Laurent Vernillet
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

9.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.

Authors:  Reva C Lawrence; David T Felson; Charles G Helmick; Lesley M Arnold; Hyon Choi; Richard A Deyo; Sherine Gabriel; Rosemarie Hirsch; Marc C Hochberg; Gene G Hunder; Joanne M Jordan; Jeffrey N Katz; Hilal Maradit Kremers; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2008-01

10.  Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.

Authors:  H Ralph Schumacher; Judith A Boice; David I Daikh; Saurabh Mukhopadhyay; Kerstin Malmstrom; Jennifer Ng; Guillermo A Tate; Javier Molina
Journal:  BMJ       Date:  2002-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.